TY - JOUR AU - Savani, Malvi AU - Murugan, Paari AU - Skubitz, Keith M. PY - 2019 DA - 2019/01/15 TI - Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure JO - Clinical Sarcoma Research SP - 1 VL - 9 IS - 1 AB - Doxorubicin is one of the most active drugs available for the treatment of sarcoma. Pegylated-liposomal doxorubicin (PLD) is a formulation of doxorubicin in which the doxorubicin is encapsulated in liposomes coated with methoxypoly (ethylene glycol); this formulation results in decreased uptake by the reticuloendothelial system, higher concentrations of drug in tumor, and less toxicity, including reduced cardiotoxicity, nausea, alopecia, and myelosuppression. No premedication is necessary. While PLD has a better toxicity profile than free doxorubicin, there is no consensus on the relative efficacy of PLD and free doxorubicin in sarcoma. SN - 2045-3329 UR - https://doi.org/10.1186/s13569-018-0111-0 DO - 10.1186/s13569-018-0111-0 ID - Savani2019 ER -